Literature DB >> 17585311

Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects.

C Foresta1, N Caretta, D Zuccarello, A Poletti, A Biagioli, L Caretti, A Galan.   

Abstract

OBJECTIVE: We tested the effect of two phosphodiesterase type-5 (PDE5) inhibitors, sildenafil and tadalafil, on ophthalmic artery (OA) blood flow velocity and investigated the presence of the PDE5 enzyme on human retinal tissue in comparison with the PDE6 enzyme localization.
METHODS: Using Colour Doppler ultrasonography (CDU) we investigated, in 30 healthy young subjects (27.8 years of age; range, 24.3-33.7 years), the effects of a single oral dose of sildenafil (100 mg), tadalafil (20 mg), and placebo on OA blood flow velocity. Western blot for PDE6 and PDE5 protein expression was performed on frozen samples of human retina, testis, sperm, skin, and corpus cavernosum. Immunohistochemistry was performed on two ocular globes from dead donors.
RESULTS: CDU showed a relationship between the administration of PDE5 inhibitors and OA blood flow velocity modifications in a time-dependent manner. Western blot and immunohistochemical analysis showed PDE6 and PDE5 presence in human retinal tissue and gave a map of its distribution.
CONCLUSION: We demonstrated that (a) tadalafil and sildenafil are able to modify the OA flux in a time-dependent manner; (b) the PDE5 enzyme is expressed on retinal and choroid vasculature (smooth muscle and endothelial cells), on ganglion and bipolar cells; (c) human retinal tissues express the PDE6 enzyme in the rod and cone photoreceptors; (d) visual side effects after PDE5 inhibitors administration may be linked to a specific effect on the PDE5 enzyme; and (e) the PDE5 enzyme may have a physiologic role on ganglion and bipolar cells that need to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585311     DOI: 10.1038/sj.eye.6702908

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  17 in total

1.  Sildenafil accelerates anterior chamber refilling after paracentesis in sheep and rabbits.

Authors:  Rosana Gerometta; Lawrence J Alvarez; Oscar A Candia
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-01       Impact factor: 4.799

2.  Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers.

Authors:  Rosana Gerometta; Lawrence J Alvarez; Oscar A Candia
Journal:  Exp Eye Res       Date:  2011-05-30       Impact factor: 3.467

3.  Central serous chorioretinopathy due to tadalafil use.

Authors:  Fatih Mehmet Türkcü; Harun Yüksel; Alparslan Şahin; Mehmet Murat; Yaşar Bozkurt; Ihsan Çaça
Journal:  Int Ophthalmol       Date:  2012-10-14       Impact factor: 2.031

4.  Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.

Authors:  Sevdalina Nikolova; Andreas Guenther; Rajkumar Savai; Norbert Weissmann; Hossein A Ghofrani; Melanie Konigshoff; Oliver Eickelberg; Walter Klepetko; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly; Soni S Pullamsetti
Journal:  Respir Res       Date:  2010-10-27

Review 5.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.

Authors:  Amani A Fawzi; Jonathan C Chou; Gina A Kim; Stuart D Rollins; Joann M Taylor; Kathryn N Farrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

7.  Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.

Authors:  Barbara M Wirostko; Charles Tressler; Lie-Ju Hwang; Gary Burgess; Alan M Laties
Journal:  BMJ       Date:  2012-02-21

Review 8.  Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma.

Authors:  Emmanuel S Buys; Lincoln R Potter; Louis R Pasquale; Bruce R Ksander
Journal:  Front Mol Neurosci       Date:  2014-05-19       Impact factor: 5.639

Review 9.  Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.

Authors:  C Corinaldesi; L Di Luigi; A Lenzi; C Crescioli
Journal:  J Endocrinol Invest       Date:  2015-06-28       Impact factor: 4.256

10.  Sildenafil and retinopathy of prematurity risk in very low birth weight infants.

Authors:  S Samiee-Zafarghandy; J N van den Anker; M M Laughon; R H Clark; P B Smith; C P Hornik
Journal:  J Perinatol       Date:  2015-10-22       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.